From: Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience
Total number of adult patients | 70 |
Median (range) age (years) | 35.9 (19–59) |
Gender (%) | 57 (81.4%) female |
Disease subtype | 67 (95.7%) diffuse |
Median (range) disease duration (years)a | 2 (1–7) |
Organ involvement: | |
Skin n (%) | 70/70 (100%) |
Interstitial lung disease, n (%) | 59/70 (84.2%) |
Pulmonary hypertension, n (%) | 4/70 (5.7%) mild |
Heart involvement, n (%) | 32/70 (45.7%)b |
Gastrointestinal, n (%) | 57/62 (92%) |
Kidney n | 0 |
Positive anti-SCl70 antibodies, n (%) | 43/64 (67.2%) |
Previous immunosuppressive treatment: | |
Methotrexate, n (%) | 26/70 (37.1%) |
Cyclophosphamide, n (%) | 48/70 (68.6%) |
Mycophenolate mofetil, n (%) | 13/70 (18.6%) |
Rituximab, n (%) | 4/70 (5.7%) |
Transplant regimen: | |
Cyclophosphamide + ATG | 65 (92.8%) |
Fludarabine + Melphalan + ATG | 5 (7.2%) |